Retatrutide TRIUMPH-1 + TRIUMPH-2 Phase 3 Readouts Anticipated Q2-Q3 2026; Seven Total Phase 3 Trials Due This Year
Eli Lilly's TRIUMPH program for retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — has TRIUMPH-1 (general obesity without T2D, 80 weeks, 2,007 participants) and TRIUMPH-2 (obesity + T2D) reading out in Q2-Q3 2026. Both are pivotal for the planned NDA filing. The earlier TRIUMPH-4 readout in December 2025 delivered 28.7% mean weight loss at 68 weeks on 12 mg dosing with 75% knee osteoarthritis pain reduction. The full TRIUMPH program runs eight pivotal trials with >5,800 participants total: obesity, T2D, OSA, MASLD, knee OA, cardiovascular outcomes (TRIUMPH-OUTCOMES, ~10,000 patients reading out 2027), and dose-extension studies. A new safety signal noted in Phase 2 — a small uptick in mild-to-moderate hepatic enzyme elevations on 12 mg dosing — will be monitored carefully in Phase 3 readouts. Lilly's $4.5B Lebanon Indiana investment (announced May 6) targets retatrutide manufacturing capacity ahead of the 2027 approval window.